4 news items
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VANI
26 Mar 24
.
Moving forward, Vivani will focus on developing NPM-115 and its emerging pipeline of innovative miniature
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
VANI
6 Mar 24
. (NASDAQ:VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
VANI
1 Mar 24
) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
VANI
28 Feb 24
) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced positive
- Prev
- 1
- Next